DOI: 10.1111/jocs.15958
View full text | Cite
Sign up to set email alerts

Abstract: In the jungle of biomarkers that predicts long‐term outcome, there are many discrepancies and there is more evidence from single‐center retrospective studies rather than clinical trials. While some of these biomarkers such as high sensitivity troponin levels, creatine kinase (CK), and CK‐MB have demonstrated a good pattern for patients’ follow‐up, other biomarkers are still struggling to get validated and internationally renown due to the small number of patients included in the studies and their retrospective… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles